Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
Crossref DOI link: https://doi.org/10.1186/s13075-015-0516-6
Published Online: 2015-01-22
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Smolen, Josef S
Kay, Jonathan
Doyle, Mittie
Landewé, Robert
Matteson, Eric L
Gaylis, Norman
Wollenhaupt, Jürgen
Murphy, Frederick T
Xu, Stephen
Zhou, Yiying
Hsia, Elizabeth C
License valid from 2015-01-22